Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000386
English
Authors' recommendations:
Raltegravir (Isentress®) is recommended in combination with other antiretroviral medicinal products as an option for restricted use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients in accordance with British HIV Association (BHIVA) guidance.
Raltegravir (Isentress®) should be restricted for use in patients who are resistant or intolerant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or for whom these options are compromised due to drug-drug interactions.
Current AWMSG advice, No 1808, in relation to the use of raltegravir (Isentress®) in treatment-experienced adult patients with human immunodeficiency virus (HIV-1) infection remains unchanged.
AWMSG is of the opinion that raltegravir (Isentress®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=160862&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- HIV-1
- Adult
- HIV Integrase Inhibitors
- Anti-Retroviral Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.